<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03498456</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_307</org_study_id>
    <nct_id>NCT03498456</nct_id>
  </id_info>
  <brief_title>Triple Therapy With Tegoprazan in H. Pylori Positive Patients</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of a Triple Therapy With Tegoprazan, Amoxicillin, and Clarithromycin in H. Pylori Positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is designed to demonstrate the non-inferiority of tegoprazan triple therapy
      (tegoprazan, amoxicillin, and clarithromycin; hereinafter TAC) to lansoprazole triple therapy
      (lansoprazole, amoxicillin, and clarithromycin; hereinafter LAC) in terms of H. pylori
      eradication rate and to evaluate the safety of tegoprazan after oral administration of the
      therapy for 7 days, twice daily in H. pylori positive patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blind, active controlled, multicenter, Phase 3 study to
      demonstrate the non-inferiority of tegoprazan triple therapy (TAC) to lansoprazole triple
      therapy (LAC) in terms of H. pylori eradication rate and to evaluate the safety of tegoprazan
      in H. pylori positive patients after oral administration of therapy for 7 days, twice daily.
      After the treatment, UBT test will be conducted to confirm the Helicobacter pylori
      eradication.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 25, 2018</start_date>
  <completion_date type="Anticipated">February 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 6, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H. pylori eradication rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Subjects will be considered to succeed in achieving H. pylori eradication if subjects's negative UBT test.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Tegoprazan/Amoxicillin/Clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan 50 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lansoprazole/Amoxicillin/Clarithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lansoprazole 30 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan/Amoxicillin/Clarithromycin</intervention_name>
    <description>Tegoprazan 50 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.</description>
    <arm_group_label>Tegoprazan/Amoxicillin/Clarithromycin</arm_group_label>
    <other_name>Tegoprazan triple therapy (TAC)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole/Amoxicillin/Clarithromycin</intervention_name>
    <description>Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.</description>
    <arm_group_label>Lansoprazole/Amoxicillin/Clarithromycin</arm_group_label>
    <other_name>Lansoprazole triple therapy (LAC)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  H. pylori positive based on the screening test

          -  Peptic ulcer disease

        Exclusion Criteria:

          -  Prior treatment for H. pylori eradication

          -  Prior use of proton pump inhibitors (PPIs), H2 receptor blockers, at a full dosage
             within 14 days

          -  Prior use of H. pylori eradication effective antibiotics, bismuth within 14 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hwoon Yong Jung, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ah Rong Kim</last_name>
    <phone>82-2-6740-2441</phone>
    <email>ahrong.kim@cj.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eun Ji Kim</last_name>
    <phone>82-2-6740-2443</phone>
    <email>eunji.kim@cj.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2018</study_first_submitted>
  <study_first_submitted_qc>April 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

